User login
Key clinical point: A simplified system based on four clinical parameters of the flow cytometric score (MFCM-Score) was positively correlated with the Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndrome.
Major finding: No significant difference appeared between the MFCM-score and FCM-score in diagnosing myelodysplastic syndrome (P > 0.05).
Study details: The data come from 118 adults with suspected myelodysplastic syndrome. Patients were compared using the FCM and MFCM. Four parameters were used in the standard FCM scoring: myeloblast-related cluster size (myeloblast-related cells/all nucleated cell), B-progenitor-related cluster size (B-progenitor-related cells/all CD34+ cells), CD45 mean fluorescence intensity (MFI) ratio (lymphocytes/myeloid blast cells), and SSC peak channel ratio (granulocyte/lymphocyte). The MFCM simplified the scoring further by using CD19 and CD33 to separate B lymphocyte progenitor cells and myeloblasts within the CD34+CD45dimm population.
Disclosures: The study was funded by the National Natural Science Foundation of China and the Natural Science Research Project of Anhui Medical University. The researchers had no financial conflicts to disclose.
Source: Guo J et al. Am J Transl Res. 2020 Nov 15. 12(11):7449–7458.
Key clinical point: A simplified system based on four clinical parameters of the flow cytometric score (MFCM-Score) was positively correlated with the Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndrome.
Major finding: No significant difference appeared between the MFCM-score and FCM-score in diagnosing myelodysplastic syndrome (P > 0.05).
Study details: The data come from 118 adults with suspected myelodysplastic syndrome. Patients were compared using the FCM and MFCM. Four parameters were used in the standard FCM scoring: myeloblast-related cluster size (myeloblast-related cells/all nucleated cell), B-progenitor-related cluster size (B-progenitor-related cells/all CD34+ cells), CD45 mean fluorescence intensity (MFI) ratio (lymphocytes/myeloid blast cells), and SSC peak channel ratio (granulocyte/lymphocyte). The MFCM simplified the scoring further by using CD19 and CD33 to separate B lymphocyte progenitor cells and myeloblasts within the CD34+CD45dimm population.
Disclosures: The study was funded by the National Natural Science Foundation of China and the Natural Science Research Project of Anhui Medical University. The researchers had no financial conflicts to disclose.
Source: Guo J et al. Am J Transl Res. 2020 Nov 15. 12(11):7449–7458.
Key clinical point: A simplified system based on four clinical parameters of the flow cytometric score (MFCM-Score) was positively correlated with the Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndrome.
Major finding: No significant difference appeared between the MFCM-score and FCM-score in diagnosing myelodysplastic syndrome (P > 0.05).
Study details: The data come from 118 adults with suspected myelodysplastic syndrome. Patients were compared using the FCM and MFCM. Four parameters were used in the standard FCM scoring: myeloblast-related cluster size (myeloblast-related cells/all nucleated cell), B-progenitor-related cluster size (B-progenitor-related cells/all CD34+ cells), CD45 mean fluorescence intensity (MFI) ratio (lymphocytes/myeloid blast cells), and SSC peak channel ratio (granulocyte/lymphocyte). The MFCM simplified the scoring further by using CD19 and CD33 to separate B lymphocyte progenitor cells and myeloblasts within the CD34+CD45dimm population.
Disclosures: The study was funded by the National Natural Science Foundation of China and the Natural Science Research Project of Anhui Medical University. The researchers had no financial conflicts to disclose.
Source: Guo J et al. Am J Transl Res. 2020 Nov 15. 12(11):7449–7458.